The University of Southampton
University of Southampton Institutional Repository

Targeted therapeutics for lymphoma: Using biology to inform treatment

Targeted therapeutics for lymphoma: Using biology to inform treatment
Targeted therapeutics for lymphoma: Using biology to inform treatment
A significant proportion of patients with B- and T-cell aggressive non-Hodgkin lymphomas are not cured by standard of care immunochemotherapy, and recent randomised studies have failed to improve outcomes for patients with the most common type, diffuse large B-cell lymphoma. Advances in molecular biology have confirmed aggressive lymphomas to be molecularly heterogeneous, but at present biological knowledge provides limited guidance for clinical practice. This is likely to change as discovery science and targeted therapies in clinical trials begin to identify subtypes that may respond differentially to specific treatments. This chapter reviews the evidence to date and the prospects for changes to clinical practice in the future.
2197-9766
343-360
Springer
Cummin, Thomas
fcce88a2-7ed7-4bde-a5f5-3f3c834382a4
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c
Friedberg, Jonathan W.
734260ab-161f-4f22-ba92-f446fcd02d16
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Lenz, Georg
Salles, Gilles
Cummin, Thomas
fcce88a2-7ed7-4bde-a5f5-3f3c834382a4
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c
Friedberg, Jonathan W.
734260ab-161f-4f22-ba92-f446fcd02d16
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Lenz, Georg
Salles, Gilles

Cummin, Thomas, Cragg, Mark, Friedberg, Jonathan W. and Johnson, Peter (2019) Targeted therapeutics for lymphoma: Using biology to inform treatment. In, Lenz, Georg and Salles, Gilles (eds.) Agressive Lymphomas. (Hematologic Malignancies) 1 ed. Cham. Springer, pp. 343-360.

Record type: Book Section

Abstract

A significant proportion of patients with B- and T-cell aggressive non-Hodgkin lymphomas are not cured by standard of care immunochemotherapy, and recent randomised studies have failed to improve outcomes for patients with the most common type, diffuse large B-cell lymphoma. Advances in molecular biology have confirmed aggressive lymphomas to be molecularly heterogeneous, but at present biological knowledge provides limited guidance for clinical practice. This is likely to change as discovery science and targeted therapies in clinical trials begin to identify subtypes that may respond differentially to specific treatments. This chapter reviews the evidence to date and the prospects for changes to clinical practice in the future.

Text
Targeted Therapeutics for Lymphoma Using Biology to Inform Treatment - Proof
Restricted to Repository staff only
Request a copy

More information

e-pub ahead of print date: 28 December 2018
Published date: 2019

Identifiers

Local EPrints ID: 427407
URI: https://eprints.soton.ac.uk/id/eprint/427407
ISSN: 2197-9766
PURE UUID: 94c20820-608f-4e25-8638-28ff11491df7
ORCID for Mark Cragg: ORCID iD orcid.org/0000-0003-2077-089X
ORCID for Peter Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 15 Jan 2019 17:30
Last modified: 14 Mar 2019 01:49

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×